



## SECRECY AGREEMENT

dated July 03, 2014

**Metapharmaceutical Ind S.L., C/Josep Plà, n° 163, 2° 5ª, 08020 Barcelona, Spain**  
represented by its Qualified Person Dra. Miriam Miguel Sala

hereinafter referred to as **Meta**

is interested in information in respect to the products

**as per attachment one (1)**

**Transo-Pharm Handels-GmbH, Bueltbek 5, 22962 Siek, Germany**  
represented by its Chief Operating Officer Justus Dehio and  
Commercial Director Andreas Freihse

hereinafter referred to as **Transo-Pharm**

is in the position to submit additional product information – like disclosure of the name of the manufacturer, stability data etc. for the products as per attachment one.

Meta is aware that all additional product information has to be regarded as confidential and they herewith oblige themselves to keep all confidential documents and information strictly secret. Meta is not allowed to hand over any document or information to any third party (verbal or written) without the prior written approval of Transo-Pharm. The submission of any secret document to the responsible local health authorities is allowed as the only exception.

Any restricted information may be used by either party for any purpose, or disclosed by either party to any other person, to the extent only that:

- it is at the date hereof, or hereafter becomes, public knowledge through no fault of the receiving party (provided that in doing so the receiving party shall not disclose any restricted information which is not public knowledge); or
- disclosed by any third party and are not originating directly or indirectly from any party to this agreement; or
- it can be shown by the receiving party, to the reasonable satisfaction of the other party, to have been known to it prior to its being disclosed.

This agreement refers to the knowledge of the supplier, the manufacturer as well as the country of origin. It is herewith agreed that following the disclosure of the above details, Meta is not allowed to contact the manufacturer directly or indirectly with reference to the products as per attachment one without prior written approval of Transo-Pharm.

Effective date of this agreement is the date affixed on the last page hereof by the party last signing this agreement. The obligation under this Agreement shall remain in effect for ten (10) years after the date of the last disclosure of confidential information.

This agreement shall be governed by and construed and enforced in accordance with the laws of United Kingdom. The parties shall use their best endeavours to resolve amicably any differences arising out of this agreement. In the event that differences cannot be resolved amicably within 60 (sixty) days of such differences arising any dispute arising out of or in connection with the present agreement, including any question regarding its existence, validity or termination, shall be referred to and finally settled under the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators appointed in accordance with the said Rules, which rules are deemed to be incorporated by reference into this clause. If those rules do not specify other, then the number of Arbitrators shall be one. The place of Arbitration shall be London. The language to be used in arbitral proceedings shall be English.


If any part, clause or phrase of this agreement turns out to be not valid or legally not binding, or becomes invalid or legally not binding, the parties agree to only replace that part, clause or phrase of this agreement that is not valid or legally not binding by a valid or legally binding one, considering the commercial intention and the tenor of this agreement.

No amendment to any provisions of this agreement shall be binding on the parties unless it is made in writing and signed by all parties to this agreement.

Agreed to and accepted:

Siek, 09/07/2014 (Date)

Transo-Pharm Handels-GmbH

  
.....  
Justus Dehio

  
.....  
ppa. Andreas Frehse

Barcelona, 7/3/14 (Date)

Metapharmaceutical Ind S.L.

  
.....  
Miriam Miguel Sala



Attachment one (1) to the Secrecy Agreement dated July 03, 2014 between Metapharmaceutical Ind S.L., Barcelona, Spain and Transo-Pharm Handels-GmbH, Siek, Germany

The a.m. agreement relates to the following product(s):

- 1.) Levothyroxine Sodium /Manufacturer: Peptido GmbH, Germany

Agreed to and accepted:

Siek, 09/07/2014 (Date)

Barcelona, 7/3/14 (Date)

Transo-Pharm Handels-GmbH

Metapharmaceutical Ind S.L.

  
.....  
Justus Dehio

  
.....  
ppa. Andreas Freithse

  
.....  
Miriam Miguel Sala

